AIM ImmunoTech Inc. entered into exchange agreements with Streeterville Capital, LLC to convert approximately $450,000 of outstanding debt under a November 2025 promissory note into 1,921,441 shares of common stock at an average conversion price of $0.234 per share. This transaction was approved by stockholders at a special meeting on July 15, 2026. The company operates in the biotechnology industry, focusing on immunotherapy treatments.
